



1600

0304
#1618
5/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Ries, U. J. et al) Art Unit:
Serial No. : 10/050,376) Examiner:
Confirmation No. : 6171
Filed : 01/16/2002
For : Antithrombotic Compounds
Docket No. : 5/1312

Commissioner for Patents
Washington, D.C. 20231

March 7, 2002

RECEIVED

APR 12 2002

TECH CENTER 1600/2900

SUBMISSION OF ENGLISH TRANSLATION


Sir:

Please find enclosed herewith a copy of a verified English translation of the German text of the U. S. provisional application filed on February 15, 2001, identifiable by Attorney Docket No. 5/1312 PV, and thereafter accorded Serial No. 60/268,569.

Benefit of this prior provisional is claimed under 35 USC 119(e) and this translation is being submitted pursuant to 37 CFR 37(a)(5).

The Commissioner is hereby authorized to charge any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955. A triplicate of this paper is enclosed.

Respectfully submitted,


Alan R. Stempel
Attorney for Applicant(s)
Reg. No. 28,991


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4868
Date: March 7, 2002

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents
Washington, DC 20231

on March 7, 2002.


Alan R. Stempel, Reg. No. 28,991



74917

RECEIVED

APR 12 2002

TECH CENTER 1600/2900

DECLARATION

I, Jane Roberta Mann, B.A., a Translator, of Frank B. Dehn & Co., 179 Queen Victoria Street, London, EC4V 4EL, do declare that I have a competent knowledge of the English and German languages and that the document that is annexed hereto is a true and accurate translation of the German text of the U.S. provisional application which has been filed under and is identifiable by the following attorney docket number: Case 5/1312 of Boehringer Ingelheim Pharma KG.

I further declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true.

I acknowledge that wilful false statements and the like are punishable by fine or imprisonment, or both [18 U.S.C. 1001] and may jeopardize the validity of the application or any patent issuing therefrom.


Signed this 23rd day of January, 2002

74917pr1.205

Antithrombotic compounds, the preparation thereof and their use as pharmaceutical compositions

5

The present invention relates to the compounds of general formula



10

the tautomers, the stereoisomers, the mixtures, the prodrugs, the derivatives thereof which contain a group that is negatively charged under physiological conditions instead of a carboxy group, and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties.

15

The compounds of the above general formula I wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group, are valuable intermediate products for preparing the corresponding compounds of general formula I wherein R₅ denotes an amidino group optionally substituted by one or two C₁₋₃-alkyl groups. The compounds of the above general formula I with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group, as well as the tautomers, the stereoisomers, the mixtures, the prodrugs, the derivatives thereof which contain a group that is negatively charged under physiological conditions instead of a carboxy group, and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, and the stereoisomers thereof, have valuable pharmacological properties, particularly an antithrombotic activity and an inhibiting effect on factor Xa.

20

25

The present application thus relates to the new compounds of the above general formula I and the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, their preparation and use.

5

In the above general formula

- (i) m denotes the number 0,
n denotes the number 1 and

10

A denotes a straight-chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group or

15

a hydrogen atom may be replaced by the group $-(CH_2)_p-R_f$, while

p denotes one of the numbers 0, 1, 2 or 3 and

20

R_f denotes a hydroxycarbonyl, C₁₋₃-alkoxycarbonyl, aminocarbonyl, C₁₋₃-alkylaminocarbonyl, C₁₋₃-alkyl)-aminocarbonyl or C₃₋₇-cycloalkylaminocarbonyl group,

or

25

- (ii) m denotes the number 1,
n denotes the number 1 and
A denotes a bond or

30

- (iii) m denotes the number 0 or 1,
n denotes the number 0 and
A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, or

- 3 -

(iv) m denotes the number 2,
n denotes the number 0 and
A denotes a bond,

5

R₁ denotes an amino, C₁₋₅-alkylamino, C₃₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group each of which may be substituted at the amino nitrogen atom by a phenylcarbonyl or phenylsulphonyl group or by a C₁₋₃-alkyl or C₁₋₃-alkyl-carbonyl group optionally substituted in the alkyl moiety by a carboxy group or a group which
10 may be converted *in vivo* into a carboxy group,

a di-(C₁₋₅-alkyl)amino or N-(C₃₋₇-cycloalkyl)-C₁₋₅-alkylamino group, while the C₁₋₅-alkyl moiety with the exception of the 1 position may be substituted in each case by a hydroxy, C₁₋₃-alkoxy, amino, C₁₋₃-alkyl-amino or di-(C₁₋₃-alkyl)-amino group,

15

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl, aminocarbonyl, C₁₋₃-alkylamino-carbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group,

20

an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups,

a C₃₋₇-cycloalkyl-carbonyl group, whilst

25

the methylene group in the 3 or 4 position in a C₅₋₇-cycloalkyl-carbonyl group may be replaced by an -NH group wherein

the hydrogen atom of the -NH group may be replaced by a C₁₋₃-alkyl,
C₁₋₃-alkyl-carbonyl, phenylcarbonyl or phenylsulphonyl group,

30

a phenylcarbonyl or heteroarylcarbonyl group,

- 4 -

a C₁₋₃-alkyl group optionally monosubstituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, hydroxy, phenyl or a 4- to 7-membered cycloalkyleneimino group or terminally disubstituted by a phenyl group and a hydroxy group, while

5 the phenyl substituents may be substituted by an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl group wherein
10 the hydrogen atoms may be wholly or partly replaced by fluorine atoms, a hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

15 R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group or a group which may be converted *in vivo* into a carboxy group and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while

20 R₅ denotes a cyano group, an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

R₆ denotes a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl,
25 C₁₋₃-alkyl, hydroxy, hydroxy-C₁₋₃-alkyl, C₁₋₃-alkoxy, C₁₋₃-alkoxy-C₁₋₃-alkyl, carboxy, carboxy-C₁₋₃-alkyl, carboxy-C₁₋₃-alkoxy, C₁₋₄-alkoxy- carbonyl-C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group and

R₇ denotes a hydrogen, fluorine, chlorine or bromine atom or a C₁₋₃-alkyl group,
30 or a thienyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

- 5 -

while the term heteroaryl group mentioned above denotes a 5-membered heteroaryl group bound via a carbon or nitrogen atom which contains

5 an imino group optionally substituted by a C₁₋₃-alkyl group, an oxygen or sulphur atom,

 an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

10 an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

 an oxygen or sulphur atom and two nitrogen atoms,

15 or a 6-membered heteroaryl group which contains one or two nitrogen atoms,

 while a phenyl ring may be fused to the abovementioned 5- or 6-membered heteroaryl groups via two adjacent carbon atoms and the bicyclic heteroaryl groups thus formed may be bound via the heteroaromatic or carbocyclic moiety,

20


 and the unsubstituted or monosubstituted phenyl groups mentioned in the definition of the abovementioned groups, or the unsubstituted or monosubstituted phenyl moieties contained in these groups, as well as the abovementioned heteroaryl groups may additionally be substituted at a carbon atom in each case by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, unless
25 otherwise stated.

 The carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted *in vivo* into a carboxy group or by a
30 group which is negatively charged under physiological conditions,

 and moreover the amino and imino groups mentioned in the definition of the abovementioned groups may be substituted by a group which can be cleaved *in vivo*.

Such groups are described for example in WO 98/46576 and by N.M. Nielsen *et al.* in International Journal of Pharmaceutics 39, 75-85 (1987).

By a group which can be converted *in vivo* into a carboxy group is meant, for
 5 example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C₁₋₆-alkanol, a phenyl-C₁₋₃-alkanol, a C₃₋₉-cycloalkanol, while a C₅₋₈-cycloalkanol may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₅₋₈-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by
 10 a C₁₋₃-alkyl, phenyl-C₁₋₃-alkyl, phenyl-C₁₋₃-alkoxycarbonyl or C₂₋₆-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₄₋₇-cycloalkenol, a C₃₋₅-alkenol, a phenyl-C₃₋₅-alkenol, a C₃₋₅-alkynol or phenyl-C₃₋₅-alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a C₃₋₈-cycloalkyl-C₁₋₃-alkanol, a
 15 bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C₁₋₃-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula



20

wherein

R_a denotes a C₁₋₈-alkyl, C₅₋₇-cycloalkyl, phenyl or phenyl-C₁₋₃-alkyl group,

R_b denotes a hydrogen atom, a C₁₋₃-alkyl, C₅₋₇-cycloalkyl or phenyl group and

25

R_c denotes a hydrogen atom or a C₁₋₃-alkyl group,

by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl,

30

trifluoromethylcarbonylaminocarbonyl, C₁₋₆-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C₁₋₆-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C₁₋₆-alkylsulphonylaminocarbonyl group

and by a group which can be cleaved *in vivo* from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C₁₋₃-alkyl or C₁₋₃-alkoxy groups, while the substituents may be identical or different, a
5 pyridinoyl group or a C₁₋₁₆-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C₁₋₁₆-alkoxycarbonyl or C₁₋₁₆-alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,
10 butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy,
15 octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C₁₋₆-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono- or disubstituted by C₁₋₆-alkyl or C₃₋₇-cycloalkyl groups and the
20 substituents may be identical or different, a C₁₋₃-alkylsulphonyl-C₂₋₄-alkoxycarbonyl, C₁₋₃-alkoxy-C₂₋₄-alkoxy-C₂₋₄-alkoxycarbonyl, R_a-CO-O-(R_bCR_c)-O-CO-, C₁₋₆-alkyl-CO-NH-(R_dCR_e)-O-CO- or C₁₋₆-alkyl-CO-O-(R_dCR_e)-(R_dCR_e)-O-CO- group, wherein R_a to R_c are as hereinbefore defined,

25 R_d and R_e, which may be identical or different, denote hydrogen atoms or C₁₋₃-alkyl groups.

Moreover, the saturated alkyl and alkoxy moieties containing more than 2 carbon atoms mentioned in the definitions above also include the branched isomers thereof
30 such as the isopropyl, tert.butyl, isobutyl group, etc.

Preferred compounds of the above general formula I are those wherein

- (i) m denotes the number 0,
n denotes the number 1 and

5 A denotes a straight-chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced
in each case by a C₁₋₃-alkyl group or
a hydrogen atom may be replaced by the group -(CH₂)_p-R_f, while

10

p denotes one of the numbers 0, 1, 2 or 3 and

R_f denotes a hydroxycarbonyl, C₁₋₃-alkoxycarbonyl, aminocarbonyl,
C₁₋₃-alkylaminocarbonyl, C₁₋₃-alkyl)-aminocarbonyl or
15 C₃₋₇-cycloalkylamino-carbonyl group,

or

- (ii) m denotes the number 0 or 1,
20 n denotes the number 0 and

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen
atoms independently of one another may be replaced in each case by a C₁₋₃-
alkyl group,

25 R₁ denotes an amino, C₁₋₃-alkylamino or C₃₋₇-cycloalkylamino group each of which
may be substituted at the amino nitrogen atom by a C₁₋₃-alkyl, C₁₋₃-alkylcarbonyl,
carboxy-C₁₋₃-alkyl, carboxy-C₁₋₃-alkylcarbonyl or C₁₋₆-alkoxy-carbonyl-
C₁₋₃-alkyl-carbonyl group,

30 a di-(C₁₋₃-alkyl)amino or N-(C₅₋₇-cycloalkyl)-C₁₋₃-alkylamino group,

a 4- to 7-membered cycloalkyleneiminocarbonyl group optionally substituted by a C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, aminocarbonyl or C₁₋₃-alkylamino-carbonyl group, while

5 a hydrogen atom bound to a nitrogen atom may be replaced by an acetyl, phenylcarbonyl or tert.-butoxycarbonyl group,

a C₅₋₇-cycloalkyl-carbonyl group wherein the methylene group in the 3 or 4 position may be replaced by an –NH group, while

10

the hydrogen atom of the –NH group may be replaced by a C₁₋₃-alkyl, C₁₋₃-alkylcarbonyl or phenylcarbonyl group,

a phenylcarbonyl or heteroarylcarbonyl group,

15

wherein the heteroaryl moiety denotes a 6-membered heteroaryl group which contains one or two nitrogen atoms and to which a phenyl ring may be fused via one or two nitrogen atoms, while the bicyclic heteroaryl groups thus formed may be bound via the heteroaromatic or carbocyclic moiety, for example a 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, quinoxalinyl or quinazolinyl group,

20

a C₁₋₃-alkyl group optionally monosubstituted by a hydroxy or phenyl group or terminally disubstituted by a phenyl and a hydroxy group, wherein

25

the phenyl substituents may be substituted by an amidino group optionally substituted by one or two C₁₋₃-alkyl groups,

30

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, trifluoromethyl or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group and

Ar denotes a phenyl group substituted by the groups R₅, R₆ and R₇, while

5 R₅ denotes a cyano group, an amidino group optionally substituted by one or two
C₁₋₃-alkyl groups, a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, or an amino-
C₁₋₃-alkyl or C₁₋₃-alkylamino-C₁₋₃-alkyl group,

10 R₆ denotes a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, C₁₋₃-
alkyl, hydroxy, hydroxy-C₁₋₃-alkyl, C₁₋₃-alkoxy, carboxy, carboxy-C₁₋₃-alkoxy or
C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkoxy group and

R₇ denotes a hydrogen atom or a C₁₋₃-alkyl group,

15 while the unsubstituted or monosubstituted phenyl groups mentioned in the definition
of the abovementioned groups, or the unsubstituted or monosubstituted phenyl
moieties contained in these groups, as well as the abovementioned heteroaryl
groups may additionally be substituted at a carbon atom in each case by a fluorine,
chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, unless
20 otherwise stated,

but particularly those compounds wherein

(i) m denotes the number 0,
n denotes the number 1 and

25 A denotes a methylene group wherein

one or two hydrogen atoms independently of one another may be replaced
in each case by a C₁₋₃-alkyl group or

30 a hydrogen atom may be replaced by the group -(CH₂)_p-R_f, while

p denotes one of the numbers 0, 1, 2 or 3 and

R_f denotes a hydroxycarbonyl or C_{1-3} -alkoxycarbonyl group

or

- 5 (ii) m denotes the number 0,
n denotes the number 0 and
A denotes a $-CH_2-CH_2-$ group, or

- (iii) m denotes the number 1,
10 n denotes the number 0 and
A denotes a $-CH_2-$ group,

the groups R_1 to R_4 are as hereinbefore defined, but R_1 in the 4 position is bound to the phenyl group contained in formula I and

15

Ar denotes a phenyl group disubstituted by the groups R_5 and R_6 , while

- R_5 is bound in the 3 position if R_6 denotes a hydrogen atom, or is bound in the 5 position if R_6 assumes a meaning other than the hydrogen atom, and denotes an
20 amidino group optionally substituted by one or two C_{1-3} -alkyl groups, a
 C_{1-6} -alkoxy-carbonyl or phenylcarbonyl group, or an amino- C_{1-3} -alkyl or
 C_{1-3} -alkylamino- C_{1-3} -alkyl group and

- R_6 denotes a hydrogen atom or a hydroxy, C_{1-3} -alkoxy, carboxy- C_{1-3} -alkoxy or
25 C_{1-4} -alkoxy-carbonyl- C_{1-3} -alkoxy group bound in the 2 position,

the isomers and the salts thereof.

Particularly preferred compounds of general formula I are those wherein

30

- (i) m denotes the number 0,
n denotes the number 1 and
A denotes a methylene group wherein

a hydrogen atom may be replaced by a methyl, hydroxycarbonyl or C₁₋₃-alkoxy-carbonyl group,

5 R₁ is bound in the 4 position of the phenyl group of formula I and denotes

a C₅₋₇-cycloalkylamino group which may be substituted at the amino nitrogen atom by a C₁₋₃-alkylcarbonyl, carboxy-C₁₋₃-alkylcarbonyl or C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkyl-carbonyl group,

10

a 4- to 7-membered cycloalkyleneiminocarbonyl group

R₂ denotes a hydrogen atom or a C₁₋₃-alkyl or trifluoromethyl group bound in the 3 position of the phenyl group in formula I,

15

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group bound in the 2 position of the phenyl group in formula I,

R₄ denotes a hydrogen atom and

20

Ar denotes a phenyl group disubstituted by the groups R₅ and R₆, while

25 R₅ is bound in the 3 position if R₆ denotes a hydrogen atom, or is bound in the 5 position if R₆ assumes a meaning other than the hydrogen atom, and denotes an amidino group optionally substituted by a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, and

R₆ denotes a hydrogen atom or a hydroxy group bound in the 2 position,

30 as well as those compounds wherein

- (i) m denotes the number 0,
n denotes the number 0 and

- 13 -

A denotes a $-\text{CH}_2-\text{CH}_2-$ group, or

- (ii) m denotes the number 1,
n denotes the number 0 and

5 A denotes a $-\text{CH}_2-$ group,

R_1 denotes a 4- to 7-membered cycloalkyleneiminocarbonyl group bound in the 4 position of the phenyl group of formula I,

10 R_2 denotes a hydrogen atom or a substituent selected from fluorine, chlorine, bromine, C_{1-3} -alkyl and trifluoromethyl bound in the 3 position of the phenyl group in formula I,

R_3 denotes a hydrogen atom or a C_{1-3} -alkyl group bound in the 2 position of the
15 phenyl group in formula I,

R_4 denotes a hydrogen atom and

Ar denotes a phenyl group disubstituted by the groups R_5 and R_6 , wherein

20 R_5 is bound in the 5 position and denotes an amidino group optionally substituted by one or two C_{1-3} -alkyl groups, a C_{1-6} -alkoxy-carbonyl or phenylcarbonyl group and

25 R_6 denotes a hydroxy group bound in the 2 position,

the isomers and the salts thereof.

The following preferred compounds are mentioned by way of example:

- (1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine,
5
- (2) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine,
- (3) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine,
10
- (4) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,
- (5) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,
15
- (6) 2-(5-aminomethyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,
20
- (7) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}]-benzamide,
- (8) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(N-acetyl-cyclobutylamino)]-benzamide,
25
- (9) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-carboxypropionyl)amino}]-benzamide,
- (10) N-(5-carbamimidoyl-2-hydroxy-benzyl)-4-cyclopentylamino-3-methyl-benzamide,
30
- (11) ethyl (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetate and

- 15 -

(12) (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetic acid,

wherein any amidino group present may additionally be substituted by a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, and the salts thereof.

According to the invention, the compounds of general formula I are obtained by methods known *per se*, e.g. by the following processes:

a) In order to prepare a compound of general formula I wherein

(i) m denotes the number 0, n denotes the number 1 and A denotes a straight-chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group or

a hydrogen atom may be replaced by the group -(CH₂)_p-R_f, while p and R_f are as hereinbefore defined,

or


or

(ii) m and n each denote the number 1 and A denotes a bond and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are as hereinbefore defined and R₅ denotes an amidino group:

- 16 -

acylating a compound of general formula




5 wherein R_4 is as hereinbefore defined,

A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group or a hydrogen atom may be replaced by the group $-(\text{CH}_2)_p-\text{R}_f$, while p and R_f are as hereinbefore defined, or denotes a bond and

10 Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_5 denotes a cyano group and R_6 and R_7 are as hereinbefore defined,

with a carboxylic acid of general formula



15

wherein m denotes the number 0 or 1 and R_1 to R_3 are as hereinbefore defined, or with the reactive derivatives thereof and subsequently converting the cyano

20 compound thus obtained into an amidino compound.

The acylation is conveniently carried out with a corresponding halide or anhydride in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxan, benzene, toluene, acetonitrile or sulpholane optionally in the presence of an inorganic or organic base at temperatures between -20 and 200°C , but preferably at temperatures between -10 and 160°C .

25

The acylation may however also be carried out with the free acid optionally in the presence of an acid-activating agent or a dehydrating agent, e.g. in the presence of

isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrogen chloride, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole,

- 5 N,N'-carbonyldiimidazole, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium tetrafluoroborate/N-methylmorpholine, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium tetrafluoroborate/N-ethyl-diisopropylamine, N,N'-thionyl-diimidazole or triphenylphosphine/carbon tetrachloride, at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C.

10

The subsequent conversion of the cyano group into an amidino group takes place as described in process e).


- b) In order to prepare a compound of general formula I wherein m denotes the
15 number 0 or 1,

n denotes the number 0,

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, and

- 20 Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are as hereinbefore defined and R₅ denotes an amidino group:

alkylating a compound of general formula



25

wherein R₁ to R₄ are as hereinbefore defined and m denotes the number 0 or 1, with a compound of general formula



wherein A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl

5 group,

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are as hereinbefore defined and R₅ denotes a cyano group,

and Z₁ denotes a leaving group such as a halogen atom or a sulphonyloxy group, e.g. a chlorine, bromine or iodine atom or a trifluoromethylsulphonyloxy group, and

10 subsequently converting the cyano compound thus obtained into an amidino compound.

The alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetra-

15 hydrofuran, benzene/tetrahydrofuran, dioxan, dimethylsulphoxide or sulfolane with an alkylating agent such as a corresponding halide or sulphonic acid ester, e.g. with methyl iodide, ethyl bromide, dimethylsulphate or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base, conveniently at temperatures between 0 and 150°C, preferably at temperatures
20 between 0 and 100°C.

The subsequent conversion of the cyano group into an amidino group is carried out as described in process e).

25 c) In order to prepare a compound of general formula I wherein


Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are as hereinbefore defined and R₅ denotes an amidino group,

30 m denotes the number 1, n denotes the number 0 and

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, or

m denotes the number 2, n denotes the number 0 and A denotes a bond:

alkylating a compound of general formula




wherein R_4 is as hereinbefore defined,

A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, or
10 denotes a bond, and

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are as hereinbefore defined and R_5 denotes a cyano group,

with a compound of general formula



wherein R_1 to R_3 are as hereinbefore defined, m denotes the number 1 or 2 and Z_2 denotes a leaving group such as a halogen atom or a sulphonyloxy group, e.g. a
20 chlorine, bromine or iodine atom or a trifluoromethylsulphonyloxy group, and subsequently converting the resulting cyano compound into an amidino compound.

The alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene,
25 tetrahydrofuran, benzene/tetrahydrofuran, dioxan, dimethylsulphoxide or sulpholane with an alkylating agent such as a corresponding halide or sulphonic acid ester, e.g. with methyl iodide, ethyl bromide, dimethylsulphate or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base

- 20 -

conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 100°C.

The subsequent conversion of the cyano group into an amidino group is carried out
5 as described in process e).

d) In order to prepare a compound of general formula I wherein


Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while
10 R₆ and R₇ are as hereinbefore defined and R₅ denotes an amidino group,

m denotes the number 0 or 1, n denotes the number 0 and


A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, or

15

m denotes the number 2, n denotes the number 0 and A denotes a bond:
reductive alkylation of an amine of general formula



20 wherein R₁ to R₄ are as hereinbefore defined and m denotes the number 0, 1 or 2,
with an aldehyde of general formula



wherein A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms
25 atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl
group, or denotes a bond, and


Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are as hereinbefore defined and R_5 denotes a cyano group, and subsequently converting the resulting cyano compound into an amidino compound.

- 5 The reductive alkylation is however preferably carried out in the presence of a complex metal hydride such as sodium borohydride, lithium borohydride, sodium cyanoborohydride, zinc borohydride, sodium triacetoxyborohydride or borane/pyridine conveniently at a pH of 1-7 optionally in the presence of a dehydrating agent such as molecular sieve or titanium-IV-isopropoxide and at ambient temperature or with
10 hydrogen in the presence of a hydrogenation catalyst, e.g. in the presence of palladium/charcoal, at a hydrogen pressure of 1 to 5 bar, preferably at temperatures between 20°C and the boiling temperature of the solvent used. It may also be advantageous during the reaction if reactive groups are protected during the reaction by conventional protecting groups which are cleaved again by conventional methods
15 after the reaction.

The subsequent conversion of the cyano group into an amidino group is carried out as described in process e).

- 20 e) In order to prepare a compound of general formula I wherein Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are as hereinbefore defined and R_5 denotes an amidino group optionally substituted by one or two C_{1-3} -alkyl groups:

- 25 reacting a compound of general formula



optionally formed in the reaction mixture ,

wherein

R_1 to R_4 , m , n and A are as hereinbefore defined, Ar denotes a phenyl or naphthyl group substituted by the groups R_6 and R_7 , while R_6 and R_7 are as hereinbefore defined, and

- 5 Z_3 denotes an alkoxy or aralkoxy group such as the methoxy, ethoxy, n-propoxy, isopropoxy or benzyloxy group or an alkylthio or aralkylthio group such as the methylthio, ethylthio, n-propylthio or benzylthio group, with an amine of general formula



wherein

R_8 and R_9 , which may be identical or different, each denote a hydrogen atom or a C_{1-3} -alkyl group, or with the salts thereof.

15

The reaction is conveniently carried out in a solvent such as methanol, ethanol, n-propanol, tetrahydrofuran or dioxan at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C, with an amine of general formula IX or with a corresponding acid addition salt such as for example ammonium carbonate


20 or ammonium acetate.

- A compound of general formula VIII is obtained for example by reacting a corresponding cyano compound with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzyl alcohol in the presence of an acid such as
- 25 hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium salt such as triethyloxonium-tetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxan at temperatures between 0 and 50°C, but preferably at 20°C, or a corresponding nitrile with hydrogen sulphide conveniently in a solvent such as pyridine or dimethylformamide and in the presence of a base such as
- 30 triethylamine and subsequently alkylating the thioamide formed with a corresponding alkyl or aralkyl halide.

f) In order to prepare a compound of general formula I wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are as hereinbefore defined and R₅ denotes an aminomethyl, C₁₋₃-alkylaminomethyl or di-(C₁₋₃-alkyl)aminomethyl group:


5

Catalytic hydrogenation of a compound of general formula



wherein

10 Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, R₁ to R₄, R₆, R₇, A, m and n are as hereinbefore defined and R₅ denotes a cyano group, and optionally subsequent alkylation with a compound of formula



15

wherein R₁₀ denotes a C₁₋₃-alkyl group and Z₄ denotes a leaving group such as a halogen atom or a sulphonyloxy group, e.g. a chlorine, bromine or iodine atom or a trifluoromethylsulphonyloxy group.

20 The catalytic hydrogenation is carried out with hydrogen in the presence of a catalyst such as palladium/charcoal, platinum in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50°C, but preferably at ambient temperature, and at a hydrogen
25 pressure of 1 to 7 bar, but preferably 3 to 5 bar, or for example with Raney nickel preferably in methanolic ammonia solution.

The alkylation which optionally follows is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene,

- 24 -


toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, dioxan, dimethylsulphoxide or sulfolane with an alkylating agent such as a corresponding halide or sulphonic acid ester, e.g. with methyl iodide, ethyl bromide, dimethylsulphate or benzyl chloride, optionally in the presence of a tertiary organic
5 base or in the presence of an inorganic base conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 100°C.

g) In order to prepare a compound of general formula I wherein

10 m denotes the number 0, n denotes the number 0, A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while
15 R₆ and R₇ are as hereinbefore defined and R₅ denotes an amidino group:


coupling a compound of general formula



20 wherein

R₁ to R₃ are as hereinbefore defined and Z₅ denotes a leaving group such as a halogen atom or a sulphonyloxy group, e.g. a chlorine, bromine or iodine atom or a trifluoromethylsulphonyloxy group,

25 with a compound of general formula



wherein R_4 is as hereinbefore defined, A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, and

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while
5 R_6 and R_7 are as hereinbefore defined and R_5 denotes a cyano group, and subsequently converting the resulting cyano compound into an amidino compound.

The coupling reaction is conveniently carried out in a solvent such as toluene, dioxan, dimethoxyethane or tetrahydrofuran using a suitable catalyst, for example
10 bis-(tri-o-tolylphosphine)-palladium(II)-chloride, tris-(dibenzylideneacetone)-dipalladium(0)/tris-o-tolylphosphine, tris-(dibenzylideneacetone)-dipalladium(0)/tris-(2-furyl)phosphane, tris-(dibenzylideneacetone)-dipalladium(0)/2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl, tetrakis-(triphenylphosphine)-palladium(0), 1,1'-bis-(diphenylphosphino)-ferrocene-palladium-dichloride or palladium-II-acetate/
15 bis-(triphenylphosphino)-propane, preferably in the presence of a base such as sodium-tert.butoxide, bis-(trimethylsilyl)-lithium amide, potassium carbonate, caesium carbonate or triethylamine at a temperature between 0 and 150°C, preferably 20 to 100°C.

20 The subsequent conversion of the cyano group into an amidino group is carried out as described in process e).

If according to the invention a compound of general formula I is obtained which contains an amino or imino group, this may subsequently be converted with a
25 corresponding acyl derivative into a corresponding acyl compound of general formula I and/or

if a compound of general formula I is obtained which contains an esterified carboxy group, this may be converted by hydrolysis into a corresponding carboxylic acid of
30 general formula I and/or

if a compound of general formula I is obtained which contains a carboxy group, this may subsequently be converted by esterification into a corresponding ester.

The subsequent acylation is conveniently carried out with a corresponding halide or anhydride in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxan, benzene, toluene, acetonitrile or sulpholane optionally
5 in the presence of an inorganic or organic base at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C. This may however also be carried out with the free acid, optionally in the presence of an acid-activating agent or a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionylchloride, trimethylchlorosilane, hydrogen chloride, sulphuric acid,
10 methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or N,N'-thionyl diimidazole or triphenylphosphine/carbon tetrachloride, at temperatures between -20 and 200°C, but preferably at
15 temperatures between -10 and 160°C.

The subsequent hydrolysis is conveniently carried out either in the presence of an acid such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a
20 base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, water/ethanol, water/isopropanol, methanol, ethanol, water/tetrahydrofuran or water/dioxan and the subsequent decarboxylation in the presence of an acid as hereinbefore described at temperatures between -10 and 120°C, e.g. at temperatures between ambient
25 temperature and the boiling temperature of the reaction mixture.

The subsequent esterification is carried out with a corresponding alcohol, conveniently in a solvent or mixture of solvents such as methylene chloride, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxan, but
30 preferably in an excess of the alcohol used, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrochloric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid,

- 27 -

phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-carbonyldiimidazole or N,N'-thionyl-diimidazole, triphenylphosphine/carbon tetrachloride or triphenylphosphine/diethyl azodicarboxylate, optionally in the presence of a base such as potassium carbonate, N-ethyl-diisopropylamine or N,N-dimethylamino-pyridine, conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C, or with a corresponding halide in a solvent such as methylene chloride, tetrahydrofuran, dioxan, dimethylsulphoxide, dimethylformamide or acetone optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which may also simultaneously serve as the solvent, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100°C, but preferably at temperatures between -10 and 80°C.

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

For example, a protecting group for a hydroxy group may be a methoxy, benzyloxy, trimethylsilyl, acetyl, benzoyl, tert-butyl, trityl, benzyl or tetrahydropyranyl group,

protecting groups for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and

protecting groups for an amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water,

tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by ether splitting, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 100°C, preferably at temperatures between 10 and 50°C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50°C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.

A methoxybenzyl group may also be cleaved in the presence of a oxidising agent such as cerium(IV)ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures between 0 and 50°C, but preferably at ambient temperature.

A methoxy group is conveniently cleaved in the presence of boron tribromide in a solvent such as methylene chloride at temperatures between -35 and -25°C.

A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxan or ether.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50°C.

An allyloxycarbonyl group is cleaved by treating with a catalytic amount of tetrakis-(triphenylphosphine)-palladium(O), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimedone at temperatures between 0 and 100°C, preferably at ambient temperature
5 and under inert gas, or by treating with a catalytic amount of tris-(triphenylphosphine)-rhodium(I)chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo[2.2.2]octane at temperatures between 20 and 70°C.

10

The compounds of general formulae II to XI used as starting materials, some of which are known from the literature, are obtained by methods known from the literature and their preparation is also described in the Examples.

15 The chemistry of the compounds of general formula II, II', II" IV and IV' is described, for example, by Schröter in Stickstoffverbindungen II, pages 341-730, Methoden der organischen Chemie (Houben-Weyl), 4th edition, Verlag Thieme, Stuttgart 1957. The preparation of carboxylic acid derivatives of general formula III is described in Methoden der organischen Chemie (Houben-Weyl), Volume E5, Carbonsäuren und
20 Carbonsäurederivate, 4th edition, Verlag Thieme, Stuttgart 1985.

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers.

25 Thus, for example, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical enantiomers and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their
30 physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolytartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (-)-menthyloxycarbonyl.

Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

Moreover, if the new compounds of formula I contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

As already mentioned, the new compounds of general formula I and the salts thereof have valuable properties. Thus, the compounds of general formula I wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇ and R₅ denotes a cyano group are valuable intermediates for preparing the corresponding compounds of general formula I wherein R₅ denotes an amidino group optionally substituted by one or two C₁₋₃-alkyl groups. The compounds of general formula I with

the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇ and R₅ denotes a cyano group, as well as the tautomers, the stereoisomers and the physiologically acceptable salts thereof, have valuable pharmacological properties, particularly an antithrombotic activity

- 5 which is preferably based on an effect on thrombin or factor Xa, for example on a thrombin-inhibiting or factor Xa-inhibiting activity, on a prolonging effect on aPTT time and on an inhibitory effect on related serine proteases such as e.g. trypsin, urokinase, factor VIIa, factor IX, factor XI and factor XII.

- 10 For example, the compounds

(1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine-hydrochloride,

- 15 (2) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride and

(3) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}]-benzamide-hydrochloride

20

were investigated for their effect on the inhibition of factor Xa as follows:

- Method: Enzyme-kinetic measurement with chromogenic substrate. The quantity of anp-nitroaniline (pNA) released from the colourless chromogenic substrate by human
25 factor Xa is determined photometrically at 405 nm. It is proportional to the activity of the enzyme used. The inhibition of the enzyme activity by the test substance I (in relation to the solvent control) is determined at various concentrations of test substance and from this the IC₅₀ is calculated, as the concentration which inhibits the factor Xa used by 50 %.

30

Material:

Tris(hydroxymethyl)-aminomethane buffer (100 mmol) and sodium chloride (150 mMol), pH 8.0

Factor Xa (Roche), spec. activity: 10 U/0.5 ml, final concentration: 0.175 U/ml for each reaction mixture

- 5 Substrate Chromozym X (Roche), final concentration: 200 $\mu\text{Mol/l}$ for each reaction mixture

Test substance: final concentration 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 $\mu\text{Mol/l}$

10

Procedure:

- 10 μl of a 23.5-times concentrated starting solution of the test substance or solvent (control), 175 μl of tris(hydroxymethyl)-aminomethane buffer and 25 μl of a 1.65 U/ml Factor Xa working solution are incubated for 10 minutes at 37°C. After the addition of
- 15 25 μl of Chromozym X working solution (1.88 $\mu\text{Mol/l}$) the sample is measured in a photometer (SpectraMax 250) at 405 nm for 150 seconds at 37°C.

Evaluation:

- 20 1. Determining the maximum increase ($\Delta\text{OD}/\text{minutes}$) over 3 measuring points.
2. Determining the % inhibition based on the solvent control.
3. Plotting a dosage/activity curve (% inhibition vs substance concentration).
- 25 4. Determining the IC_{50} by interpolating the X value (substance concentration) of the dosage/activity curve at Y = 50 % inhibition.

The following Table shows the results obtained:

30

Substance	Inhibition of factor Xa (IC_{50} in μM)
(1)	0.084
(2)	0.014
(3)	0.075

The compounds prepared according to the invention are well tolerated, as no toxic side effects could be observed at therapeutic doses.

In view of their pharmacological properties the new compounds, with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , and R_5 denotes a cyano group, and the physiologically acceptable salts thereof are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as for example the treatment of deep leg vein thrombosis, for preventing reocclusions after bypass operations or angioplasty (PT(C)A), and occlusion in peripheral arterial diseases such as pulmonary embolism, disseminated intravascular coagulation, for preventing coronary thrombosis, stroke and the occlusion of shunts. In addition, the compounds according to the invention are suitable for antithrombotic support in thrombolytic treatment, such as for example with alteplase, reteplase, tenecteplase, staphylokinase or streptokinase, for preventing long-term restenosis after PT(C)A, for the prevention and treatment of ischaemic incidents in patients with unstable angina or non-transmural cardiac infarct, for preventing metastasis and the growth of clot-dependent tumours and fibrin-dependent inflammatory processes, e.g. in the treatment of pulmonary fibrosis. The new compounds and the physiologically acceptable salts thereof may be used therapeutically in conjunction with inhibitors of platelet aggregation such as fibrinogen receptor antagonists (e.g. abciximab, eptifibatide, tirofiban), with inhibitors of ADP-induced aggregation (e.g. clopidogrel, ticlopidine), with P_2T receptor antagonists (e.g. cangrelor) or with combined thromboxane receptor antagonists/synthetase inhibitors (e.g. terbogrel).

The dosage required to achieve such an effect is appropriately 3 to 30 mg/kg, preferably 1 to 10 mg/kg by intravenous route, and 5 to 50 mg/kg, preferably 3 to 30 mg/kg by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard

- 34 -

fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.

The Examples which follow are intended to illustrate the invention:

5

Example 1

2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine-hydrochloride

5

a. 2-methyl-4-bromo-benzoic acid-pyrrolidinamide

35 g (0.163 mol) of 2-methyl-4-bromo-benzoic acid are dissolved in 1 l tetrahydrofuran and 100 ml water and combined with 57.8 g (0.18 mol) of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, 22.0 g (0.163 mol) of N-hydroxybenzotriazole and 62.7 ml (0.36 mol) of ethyl-dicyclohexylamine. After 10 minutes at ambient temperature 13.9 ml (0.167 mol) of pyrrolidine are added. The reaction mixture is stirred for 24 hours and evaporated down. The residue is combined with 5 % saline solution/methylene chloride and extracted. The aqueous phase is extracted three times with methylene chloride, the combined organic phases are dried and evaporated down. The residue is purified on silica gel, eluting with methylene chloride plus ethanol (0-3%). The uniform fractions are combined and evaporated down.

10

15

Yield: 42 g (77 % of theoretical),

R_f value: 0.45 (dichloromethane/ethanol = 95:5)

20

b. N-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-acetamide

1.9 g (9.8 mmol) of N-[2-(2-methoxy-phenyl)-ethyl]-acetamide are dissolved in 50 ml acetonitrile and after the addition of 2 g (11 mmol) of N-bromosuccinimide stirred for 4 hours at ambient temperature. Then the solvent is distilled off, the residue is stirred with dichloromethane and suction filtered. The mother liquor is evaporated down and chromatographed on silica gel, eluting with dichloromethane/methanol/ammonia (50:0.9:0.1).

25

Yield: 2.6 g (99 % of theoretical),

R_f value: 0.47 (silica gel; dichloromethane/methanol/ammonia = 24:0.9:0.1)

30

c. N-[2-(5-cyano-2-methoxy-phenyl)-ethyl]-acetamide

12.5 g (45.9 mmol) of N-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-acetamide are dissolved in 50 ml dimethylformamide and after the addition of 8.2 g (91 mmol) of

copper cyanide, 577 mg (0.5 mmol) of tetrakis-triphenylphosphine-palladium-(0) and 11.6 g aluminium oxide stirred for 20 hours under a nitrogen atmosphere at 140°C. The warm suspension is suction filtered and the mother liquor is evaporated down. The residue is chromatographed on silica gel, eluting with dichloromethane/ethanol
5 (0-3%).

Yield: 4.9 g (49 % of theoretical),

R_f value: 0.35 (silica gel; dichloromethane/methanol/ammonia = 19:0.9:0.1)

d. (5-cyano-2-methoxy-phenyl)-ethylamine

10 4.9 g (22.4 mmol) of N-[2-(5-cyano-2-methoxy-phenyl)-ethyl]-acetamide are dissolved in 20 ml glacial acetic acid and after the addition of 60 ml of 3 molar hydrochloric acid refluxed for 15 hours. Then the solvent is distilled off, the residue is triturated in acetone and suction filtered. The crude product is dissolved in water, made alkaline with conc. ammonia and extracted with ethyl acetate. The organic phase is dried and
15 evaporated down.

Yield: 2.6 g (66 % of theoretical),

R_f value: 0.51 (silica gel; dichloromethane/methanol/ammonia = 4:0.9:0.1)

20 e. 2-(5-cyano-2-methoxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine

A solution of 2.0 g (6.7 mmol) of 2-methyl-4-bromo-benzoic acid-pyrrolidinamide and 1.9 g (8.5 mmol) of (5-cyano-2-methoxy-phenyl)-ethylamine in 75 ml toluene is combined under a nitrogen atmosphere with 5.7 g (17.5 mmol) of caesium carbonate, 120 mg (0.27 mmol) of palladium-II-acetate and 240 mg (0.385 mmol) of 2,2'-bis-
25 (diphenylphosphino)-1,1'-binaphthyl (BINAP) and heated to 130°C for 18 hours. After cooling the reaction mixture is stirred with ice water and extracted with methylene chloride. The organic phase is washed with water, dried over magnesium sulphate and evaporated down. The crude product is purified on silica gel, eluting with methylene chloride/methanol/ammonia (1/0/0; 50/0.9/0.1 and 33/0.9/0.1).

30 Yield: 0.9 g (37 % of theoretical),

R_f value: 0.71 (silica gel; dichloromethane/methanol/ammonia = 9:0.9:0.1)

f. 2-(5-cyano-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine

0.5 g (1.3 mmol) of 2-(5-cyano-2-methoxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine are dissolved in 40 ml dichloromethane and combined
5 with 7 ml (7 mmol) of boron tribromide (1 M solution in dichloromethane) at -45 to -25°C. The reaction mixture is stirred for 20 hours at ambient temperature, combined with ice and conc. ammonia and extracted with dichloromethane/methanol (19:1). The combined organic extracts are evaporated down and chromatographed on silica gel, eluting with dichloromethane/ethanol (0-3%).
10 Yield: 0.2 g (46 % of theoretical),
R_f value: 0.42 (silica gel; ethyl acetate/toluene/ammonia = 9:0.9:0.1)

g. 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine-hydrochloride

15 0.2 g (0.63 mmol) of 2-(5-cyano-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine are dissolved in ethanolic hydrochloric acid and stirred for 4.75 hours at ambient temperature. The reaction mixture is evaporated down, taken up in 25 ml ethanol and combined with 0.9 g (9.5 mmol) of ammonium carbonate. After 18 hours at ambient temperature the undissolved material is filtered
20 off and the filtrate evaporated down. The residue is triturated with ether, filtered, washed with ether and dried.
Yield: 0.2 g (87 % of theoretical),
R_f value: 0.58 (Reversed Phase RP 8; 5% sodium chloride solution/methanol = 1:2)
C₂₁H₂₆N₄O₂ x HCl (366.47/402.93)
25 Mass spectrum : (M+H)⁺ = 367
(M+Cl)⁻ = 401/03 (Cl)

Example 2

2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzylamine-hydrochloride

5

a. 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzonitrile

Prepared analogously to Example 1.c. from 2-methyl-4-bromo-benzoic acid-pyrrolidinamide, copper cyanide, tetrakis-triphenylphosphine-palladium-(0) and aluminium oxide in dimethylformamide.

10 Yield: 39 % of theoretical,

R_f value: 0.22 (silica gel; cyclohexane/ethyl acetate = 1:1)

b. 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzylamine

2.3 g 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzonitrile are dissolved in 75 ml
15 ethanolic ammonia and after the addition of 0.4 g Raney nickel hydrogenated for 3 hours at 70°C with hydrogen. Then the catalyst is filtered off and the filtrate is evaporated down.

Yield: 2.3 g (100 % of theoretical),

R_f value: 0.45 (silica gel; dichloromethane/ethanol = 9:1)

20

c. 2-(5-cyano-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine

A solution of 1.1 g (5 mmol) of 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzylamine in
10 ml methanol is combined with 0.3 ml (5 mmol) of glacial acetic acid and 0.2 g (3.5
25 mmol) of sodium cyanoborohydride. After 15 minutes 0.5 g (3.4 mmol) of 3-formyl-4-hydroxy-benzonitrile are added. The reaction mixture is stirred for 2 hours at ambient temperature and combined with ice and hydrochloric acid. By adding conc. ammonia the solution is adjusted to pH 8 and extracted with dichloromethane. The organic phase is evaporated down and chromatographed over silica gel, eluting with ethyl
30 acetate.

Yield: 0.6 g (32 % of theoretical),

R_f value: 0.33 (silica gel; dichloromethane/ethanol = 19:1)

d. 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine-hydrochloride

Prepared analogously to Example 1.g. from 2-(5-cyano-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 98 % of theoretical,

R_f value: 0.66 (Reversed Phase RP 8; 5% sodium chloride solution/methanol = 1:1)

C₂₁H₂₆N₄O₂ x HCl (366.47/402.93)

10 Mass spectrum : (M+H)⁺ = 367
(M-H)⁻ = 365
(M+Cl)⁻ = 401/03 (Cl)

The following compound is prepared analogously to Example 2:

15

(1) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine-dihydrochloride

Yield: 27 % of theoretical,

R_f value: 0.6 (Reversed Phase RP 8; 5% sodium chloride solution/methanol = 2:3)

20 C₂₂H₂₈N₄O₂ x 2 HCl (380.49/453.41)

Mass spectrum : (M+H)⁺ = 381

Example 3

25 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride

a. 4-benzyloxy-3-hydroxymethyl-benzonitrile

A solution of 1.7 g (6.9 mmol) of 4-benzyloxy-3-formyl-benzonitrile in 10 ml tetrahydrofuran at 5-10°C is added dropwise to a solution of 0.15 g (3.9 mmol) of sodium borohydride in 20 ml tetrahydrofuran. After 1.5 hours at 10°C the solvent is distilled off. The residue is combined with 0.5 N sodium hydroxide solution and

30

extracted with ethyl acetate. The organic phase is dried, evaporated down and crystallised with ether/petroleum ether.

Yield: 1.5 g (91 % of theoretical),

R_f value: 0.2 (silica gel; petroleum ether/ethyl acetate = 8:2)

5

b. 4-benzyloxy-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-methyl-benzonitrile

A solution of 2.6 g (15 mmol) of diethyl azodicarboxylate in 5 ml tetrahydrofuran is added dropwise at ambient temperature to a solution of 0.9 g (6.2 mmol) of phthalimide potassium salt, 1.5 g (6.2 mmol) of 4-benzyloxy-3-hydroxymethyl-

10 benzonitrile and 3.9 g (15 mmol) of triphenylphosphine in 50 ml tetrahydrofuran, while the temperature rises to 42°C. After 24 hours the solvent is distilled off, the residue is taken up in sodium chloride solution/ethyl acetate and extracted with ethyl acetate. The combined organic extracts are dried and chromatographed on silica gel, eluting with petroleum ether/ethyl acetate (10:0, 9:1 and 8:2).

15 Yield: 0.7 g (31 % of theoretical),

R_f value: 0.45 (silica gel; petroleum ether/ethyl acetate = 7:3)

c. 4-benzyloxy-3-aminomethyl-benzonitrile

0.7 g (1.9 mmol) of 4-benzyloxy-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-methyl-
20 benzonitrile are dissolved in 20 ml isopropanol and refluxed for 30 minutes with the addition of 1.5 ml of hydrazine hydrate. Then the reaction solution is evaporated down, the residue is stirred with ice water, suction filtered and dried.

Yield: 0.3 g (71 % of theoretical),

R_f value: 0.1 (silica gel; petroleum ether/ethyl acetate = 1:1)

25

d. 3-methyl-4-(pyrrolidin-1-carbonyl)-benzoic acid

26.8 g (0.1 mol) of 3-methyl-4-(pyrrolidin-1-carbonyl)-bromobenzene, 11.9 ml (0.13 mol) of n-butanol, 1 g (0.004 mol) of palladium-II-acetate, 4.2 g (0.016 mol) of tri-
phenylphosphine and 15.5 ml (0.12 mol) of N-ethyl-diisopropylamine are placed in a
30 steel bomb and after the addition of carbon monoxide heated for 50 hours to 100°C. After cooling and evaporating off the carbon monoxide the reaction solution is stirred into ice water and extracted with ethyl acetate. The organic phase is dried and evaporated down. The residue is taken up in sodium hydrogen carbonate solution

and ethyl acetate, the aqueous phase is adjusted to pH 4 with hydrochloric acid and extracted with ethyl acetate. The organic phases are dried and evaporated down.

Yield: 0.8 g (3.4 % of theoretical),

R_f value: 0.4 (silica gel; dichloromethane/ethanol = 19:1)

5

e. 2-(2-benzyloxy-5-cyano-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride

Prepared analogously to Example 1.a. from 3-methyl-4-(pyrrolidin-1-carbonyl)-benzoic acid, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, N-methylmorpholine and 4-benzyloxy-3-aminomethyl-benzonitrile in dimethylformamide.

10

Yield: 93 % of theoretical,

R_f value: 0.5 (silica gel; dichloromethane/ethanol = 9:1)

15

f. 2-(5-carbamimidoyl-2-benzyloxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride

Prepared analogously to Example 1.g. from 2-(2-benzyloxy-5-cyano-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride and hydrochloric acid/ammonium carbonate in ethanol.

20

Yield: 0.3 g (77 % of theoretical),

R_f value: 0.3 (silica gel; dichloromethane/ethanol/glacial acetic acid = 8:2 + 1% glacial acetic acid)

25

g. 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride

0.3 g (0.5 mmol) of 2-(5-carbamimidoyl-2-benzyloxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride are dissolved in 50 ml methanol and after the addition of 200 mg palladium on activated charcoal (10%) hydrogenated with 5 atmospheres of hydrogen at ambient temperature. Then the catalyst is filtered off, the filtrate is evaporated down and triturated with petroleum ether/ether (1:1).

30

Yield: 120 mg (58 % of theoretical),

C₂₁H₂₄N₄O₃ x HCl (380.45/416.91)

Mass spectrum : $(M+H)^+ = 381$
 $(M-H)^- = 379$

The following compound is prepared analogously to Example 3:

5

(1) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide-hydrochloride

Yield: 81 % of theoretical,

R_f value: 0.55 (Reversed Phase RP 8; 5% sodium chloride solution/methanol = 2:3)

10 C₂₂H₂₆N₄O₃ x HCl (394.48/430.94)

Mass spectrum : $(M+H)^+ = 395$
 $(M-H)^- = 393$
 $(M+Cl)^- = 429/31 (Cl)$

15

Example 4

2-(5-aminomethyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide

20 Prepared analogously to Example 2.b. from 2-(5-cyano-2-benzyloxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide in methanolic ammonia/Raney nickel/hydrogen and subsequent reaction analogously to Example 3.g. with hydrogen in methanol with the addition of palladium on activated charcoal.

Yield: 34 % of theoretical,

25 R_f value: 0.35 (silica gel; dichloromethane/ethanol = 8:2)

C₂₁H₂₅N₃O₃ (367.45)

Mass spectrum : $(M-H)^- = 366$

Example 5

2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxy-carbonylpropionyl)amino}]-benzamide-hydrochloride

5

a. benzyl 4-cyclopentylamino-3-methyl-benzoate

3.3 g (13.6 mmol) of benzyl 4-amino-3-methyl-benzoate, 1.3 ml (15 mmol) of cyclopentanone, 1.2 ml (20.5 mmol) of glacial acetic acid and 0.1 g of p-toluenesulphonic acid are dissolved in 70 ml tetrahydrofuran and stirred for 30 minutes at ambient
10 temperature. Then 4.0 g (17.8 mmol) of sodium triacetoxymethylborohydride are added. After 26 hours at ambient temperature the solvent is distilled off and the residue is distributed in water/ ethyl acetate. The aqueous phase is extracted three times with ethyl acetate. The combined organic extracts are dried and purified over silica gel, eluting with dichloromethane.

15 Yield: 0.8 g (19 % of theoretical),

R_f value: 0.78 (silica gel; dichloromethane/ethanol = 95:5)

b. benzyl 4-[cyclopentyl-(3-ethoxycarbonyl-propionyl)-amino]-3-methyl-benzoate

A solution of 0.8 g (2.6 mmol) of benzyl 4-cyclopentylamino-3-methyl-benzoate in 30
20 ml tetrahydrofuran is combined with 0.1 g (2.6 mmol) of sodium hydride and heated to 40°C for one hour. After the addition of 0.3 ml (2.34 mmol) of ethyl succinate chloride the reaction mixture is stirred for 5 days at ambient temperature. After evaporation of the solvent the residue is taken up in ethyl acetate, washed with saline solution and dried. The crude product is purified on silica gel, eluting with
25 dichloromethane.

Yield: 0.8 g (73 % of theoretical),

R_f value: 0.64 (silica gel; dichloromethane/ethanol = 95:5)

c. 4-[cyclopentyl-(3-ethoxycarbonyl-propionyl)-amino]-3-methyl-benzoic acid

30 Prepared analogously to Example 3.g. from benzyl 4-[cyclopentyl-(3-ethoxycarbonyl-propionyl)-amino]-3-methyl-benzoate and palladium on activated charcoal/hydrogen in methanol.

Yield: 91 % of theoretical,

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 95:5)

d. 2-(5-cyano-2-benzyloxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonyl-propionyl)amino}]-benzamide

- 5 Prepared analogously to Example 1.a. from 4-[cyclopentyl-(3-ethoxycarbonyl-propionyl)-amino]-3-methyl-benzoic acid, 4-benzyloxy-3-aminomethyl-benzonitrile, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and N-methylmorpholine in dimethylformamide.

Yield: 95 % of theoretical,

- 10 R_f value: 0.28 (silica gel; dichloromethane/ethanol = 95:5)

e. 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}]-benzamide-hydrochloride

- 15 Prepared analogously to Example 1.g. from 2-(5-cyano-2-benzyloxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}-benzamide and hydrochloric acid/ammonium carbonate in ethanol and subsequent reaction analogously to Example 3.g. with hydrogen in methanol with the addition of palladium on activated charcoal.

Yield: 51 % of theoretical,

- 20 R_f value: 0.31 (Reversed Phase RP 8; 5% sodium chloride solution/methanol = 6:4)
C₂₇H₃₄N₄O₅ x HCl (494.60/531.06)

Mass spectrum : (M+H)⁺ = 495

(M+Cl)⁻ = 529/31 (Cl)

- 25 The following compound is prepared analogously to Example 5:

(1) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(N-acetyl-N-cyclobutyl-amino)]-benzamide-hydrochloride

Yield: 97 % of theoretical,

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

- 30 C₂₂H₂₆N₄O₃ x HCl (394.48/430.94)

Mass spectrum : (M+H)⁺ = 395

(M-H)⁻ = 393

(M+Cl)⁻ = 429/31 (Cl)

Example 6

2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-N-(3-carboxy-propionyl)amino}]-benzamide-hydrochloride

- 5 0.2 g (0.28 mmol) of 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}]-benzamide-hydrochloride are stirred in 5 ml of 6 molar hydrochloric acid at ambient temperature for 4 hours. The solvent is distilled off and the residue is purified on Reversed Phase RP 8, eluting with water/methanol (0 - 50%).
- 10 Yield: 99 % of theoretical,
R_f value: 0.49 (Reversed Phase RP 18; 5% sodium chloride solution/methanol = 6:4)
C₂₅H₃₀N₄O₅ x HCl (466.54/503.00)
Mass spectrum : (M+H)⁺ = 467
(M-H)⁻ = 465
15 (M+Na)⁺ = 489

Example 7

- N-(5-carbamimidoyl-2-hydroxy-benzyl)-4-cyclopentylamino-3-methyl-benzamide-
20 hydrochloride

a. methyl 4-cyclopentylamino-3-methyl-benzoate

- Prepared analogously to Example 1.e. from methyl 4-bromo-3-methyl-benzoate, cyclopentylamine, caesium carbonate, palladium-II-acetate and 2,2'-bis-(diphenyl-
25 phosphino)-1,1'-binaphthyl in toluene.
Yield: 95 % of theoretical,
R_f value: 0.55 (silica gel; dichloromethane)

b. 4-cyclopentylamino-3-methyl-benzoic acid

- 30 3.3 g (14 mmol) of methyl 4-cyclopentylamino-3-methyl-benzoate are dissolved in 5 ml methanol and combined with 30 ml of sodium hydroxide solution (2N). After 12 hours at ambient temperature the reaction mixture is evaporated down and combined with 30 ml hydrochloric acid (2N) with cooling. After 30 minutes the solution is

combined with dichloromethane and extracted. The organic phase is dried and evaporated down.

Yield: 0.8 g (26 % of theoretical),

R_f value: 0.74 (silica gel; petroleum ether/ethyl acetate = 4:6)

5

c. N-(2-benzyloxy-5-cyano-benzyl)-4-cyclopentylamino-3-methyl-benzamide

Prepared analogously to Example 1.a. from 4-cyclopentylamino-3-methyl-benzoic acid, O-(benzotriazol-1-yl)-N,N,N'-N'-tetramethyluronium fluoroborate, N-methylmorpholine and 4-benzyloxy-3-aminomethyl-benzonitrile in dimethylformamide.

10

Yield: 49 % of theoretical,

R_f value: 0.77 (silica gel; dichloromethane/ethanol = 95:5)

d. N-(5-carbamimidoyl-2-hydroxy-benzyl)-4-cyclopentylamino-3-methyl-benzamide-hydrochloride

15

Prepared analogously to Example 1.g. from N-(2-benzyloxy-5-cyano-benzyl)-4-cyclopentylamino-3-methyl-benzamide and hydrochloric acid/ammonium carbonate in ethanol and subsequent reaction with hydrogen/palladium on activated charcoal in methanol analogously to Example 3.g.

20

Yield: 78 % of theoretical,

R_f value: 0.29 (silica gel; dichloromethane/ethanol = 4:1)

C₂₁H₂₆N₄O₂ x HCl (366.47/402.93)

Mass spectrum : (M+H)⁺ = 367

(M-H)⁻ = 365

25

(M+Cl)⁻ = 401/03 (Cl)

Example 8

Ethyl (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetate-acetate

5

a. benzyl tert-butoxycarbonylamino-(3-cyano-phenyl)-acetate

Prepared analogously to Example 1.c. from benzyl tert-butoxycarbonylamino-(3-bromo-phenyl)-acetate and copper-(I)-cyanide/ tetrakis-triphenylphosphine-palladium-(0).

10 Yield: 41% of theoretical,

R_f value: 0.25 (silica gel; cyclohexane/ethyl acetate = 4:1)

b. benzyl amino-(3-cyano-phenyl)-acetate

Prepared analogously to Example 1.d. from benzyl tert-butoxycarbonylamino-(3-cyano-phenyl)-acetate and hydrochloric acid in dioxan.

15

Yield: 66% of theoretical,

R_f value: 0.4 (silica gel; dichloromethane/methanol = 95:5 + ammonia)

c. benzyl (3-cyano-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)acetate

20

Prepared analogously to Example 1.a. from benzyl amino-(3-cyano-phenyl)-acetate and 3-methyl-4-(pyrrolidin-1-carbonyl)-benzoic acid, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and N-methylmorpholine in dimethylformamide.

Yield: 93% of theoretical,

25

R_f value: 0.5 (silica gel; ethyl acetate)

d. Ethyl (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetate-acetate

Prepared analogously to Example 1.g. from benzyl (3-cyano-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)acetate and hydrochloric acid/ammonium carbonate in ethanol.

30

Yield: 47% of theoretical,

R_f value: 0.46 (Reversed Phase RP8; 5% saline solution/methanol = 2:3)

$C_{24}H_{28}N_4O_4 \times CH_3COOH$ (436.52/496.57)

Mass spectrum : $(M+H)^+ = 437$

$(M-H)^- = 435$

5 Example 9

(3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetic acid-hydrochloride

10 Prepared analogously to Example 7.b. from ethyl (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetate and sodium hydroxide solution.

Yield: 91% of theoretical,

R_f value: 0.55 (Reversed Phase RP8; 5% saline solution/methanol = 2:3)

$C_{22}H_{24}N_4O_4 \times HCl$ (408.46/444.92)

15 Mass spectrum : $(M+H)^+ = 409$

$(M+Na)^+ = 431$

Example 10

20 Dry ampoule containing 75 mg of active substance per 10 ml

Composition:

25	Active substance	75.0 mg
	Mannitol	50.0 mg
	water for injections	ad 10.0 ml

Preparation:

Active substance and mannitol are dissolved in water. After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.

5

Example 11

Dry ampoule containing 35 mg of active substance per 2 ml

10

Composition:

Active substance	35.0 mg
15 Mannitol	100.0 mg
water for injections	ad 2.0 ml

Preparation:

Active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried.

20

To produce the solution ready for use, the product is dissolved in water for injections.

Example 12

25

Tablet containing 50 mg of active substance

Composition:

30

(1) Active substance	50.0 mg
(2) Lactose	98.0 mg
(3) Maize starch	50.0 mg
(4) Polyvinylpyrrolidone	15.0 mg
35 (5) Magnesium stearate	<u>2.0 mg</u>
	215.0 mg

Preparation:

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5)
5 is added to the dried granulated material. From this mixture tablets are pressed,
biphanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 9 mm.

10 Example 13

Tablet containing 350 mg of active substance

15 Composition:

	(1) Active substance	350.0 mg
	(2) Lactose	136.0 mg
	(3) Maize starch	80.0 mg
20	(4) Polyvinylpyrrolidone	30.0 mg
	(5) Magnesium stearate	<u>4.0 mg</u>
		600.0 mg

Preparation:

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5)
25 is added to the dried granulated material. From this mixture tablets are pressed,
biphanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 12 mm.

Example 14

Capsules containing 50 mg of active substance

5 Composition:

	(1) Active substance	50.0 mg
	(2) Dried maize starch	58.0 mg
	(3) Powdered lactose	50.0 mg
10	(4) Magnesium stearate	<u>2.0 mg</u>
		160.0 mg

Preparation:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with
15 vigorous mixing.

This powder mixture is packed into size 3 hard gelatine capsules in a capsule filling
machine.

20

Example 15

Capsules containing 350 mg of active substance

25 Composition:

	(1) Active substance	350.0 mg
	(2) Dried maize starch	46.0 mg
	(3) Powdered lactose	30.0 mg
30	(4) Magnesium stearate	<u>4.0 mg</u>
		430.0 mg

Preparation:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with
35 vigorous mixing.

- 52 -

This powder mixture is packed into size 0 hard gelatine capsules in a capsule filling machine.

Example 16

5

Suppositories containing 100 mg of active substance

1 suppository contains:

10	Active substance	100.0 mg
	Polyethyleneglycol (M.W. 1500)	600.0 mg
	Polyethyleneglycol (M.W. 6000)	460.0 mg
	Polyethylenesorbitan monostearate	<u>840.0 mg</u>
		2,000.0 mg

15


Preparation:

The polyethyleneglycol is melted together with polyethylenesorbitan monostearate. At 40°C the ground active substance is homogeneously dispersed in the melt. This is then cooled to 38°C and poured into slightly chilled suppository moulds.

20

Patent Claims

5 1. Compounds of general formula



(i) m denotes the number 0,

n denotes the number 1 and

10 A denotes a straight-chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced
in each case by a C₁₋₃-alkyl group or

15 a hydrogen atom may be replaced by the group $\text{---}(\text{CH}_2)_p\text{---R}_f$, while

p denotes one of the numbers 0, 1, 2 or 3 and

R_f denotes a hydroxycarbonyl, C₁₋₃-alkoxycarbonyl, aminocarbonyl,

20 C₁₋₃-alkylaminocarbonyl, C₁₋₃-alkyl)-aminocarbonyl or

C₃₋₇-cycloalkylaminocarbonyl group,

or

25 (ii) m denotes the number 1,

n denotes the number 1 and

A denotes a bond or

(iii) m denotes the number 0 or 1,

n denotes the number 0 and

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C₁₋₃-alkyl group, or

5

- (iv) m denotes the number 2,
n denotes the number 0 and
A denotes a bond,

- 10 R₁ denotes an amino, C₁₋₅-alkylamino, C₃₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group each of which may be substituted at the amino nitrogen atom by a phenylcarbonyl or phenylsulphonyl group or by a C₁₋₃-alkyl or C₁₋₃-alkyl-carbonyl group optionally substituted in the alkyl moiety by a carboxy group or a group which may be converted *in vivo* into a carboxy group,

15

a di-(C₁₋₅-alkyl)amino or N-(C₃₋₇-cycloalkyl)-C₁₋₅-alkylamino group, while the C₁₋₅-alkyl moiety with the exception of the 1 position may be substituted in each case by a hydroxy, C₁₋₃-alkoxy, amino, C₁₋₃-alkyl-amino or di-(C₁₋₃-alkyl)-amino group,

- 20 a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl, aminocarbonyl, C₁₋₃-alkylamino-carbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group,

- 25 an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups,

a C₃₋₇-cycloalkyl-carbonyl group, whilst

30

the methylene group in the 3 or 4 position in a C₅₋₇-cycloalkyl-carbonyl group may be replaced by an -NH group wherein

the hydrogen atom of the -NH group may be replaced by a C₁₋₃-alkyl, C₁₋₃-alkyl-carbonyl, phenylcarbonyl or phenylsulphonyl group,

a phenylcarbonyl or heteroarylcarbonyl group,

5 a C₁₋₃-alkyl group optionally monosubstituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, hydroxy, phenyl or a 4- to 7-membered cycloalkyleneimino group or terminally disubstituted by a phenyl group and a hydroxy group, while

10 the phenyl substituents may be substituted by an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

15 R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl group wherein the hydrogen atoms may be wholly or partly replaced by fluorine atoms, a hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

20 R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group or a group which may be converted *in vivo* into a carboxy group and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while

25 R₅ denotes a cyano group, an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

30 R₆ denotes a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, C₁₋₃-alkyl, hydroxy, hydroxy-C₁₋₃-alkyl, C₁₋₃-alkoxy, C₁₋₃-alkoxy-C₁₋₃-alkyl, carboxy, carboxy-C₁₋₃-alkyl, carboxy-C₁₋₃-alkoxy, C₁₋₄-alkoxy- carbonyl-C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group and

R₇ denotes a hydrogen, fluorine, chlorine or bromine atom or a C₁₋₃-alkyl group,

or a thienyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

while the term heteroaryl group mentioned above denotes a 5-membered heteroaryl
5 group bound via a carbon or nitrogen atom which contains

an imino group optionally substituted by a C₁₋₃-alkyl group, an oxygen or sulphur atom,

10 an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

15 an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroaryl group which contains one or two nitrogen atoms,

20 while a phenyl ring may be fused to the abovementioned 5- or 6-membered heteroaryl groups via two adjacent carbon atoms and the bicyclic heteroaryl groups thus formed may be bound via the heteroaromatic or carbocyclic moiety,

and the unsubstituted or monosubstituted phenyl groups mentioned in the definition
25 of the abovementioned groups, or the unsubstituted or monosubstituted phenyl moieties contained in these groups, as well as the abovementioned heteroaryl groups may additionally be substituted at a carbon atom in each case by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, unless otherwise stated,

30 the carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted *in vivo* into a carboxy group or by a group which is negatively charged under physiological conditions, and

the amino and imino groups mentioned in the definition of the abovementioned groups may be substituted by a group which can be cleaved *in vivo*,

5 the isomers and the salts thereof.

2. Compounds of general formula I according to claim 1, wherein

10 (i) m denotes the number 0,
n denotes the number 1 and

A denotes a straight-chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced
15 in each case by a C₁₋₃-alkyl group or
a hydrogen atom may be replaced by the group $-(CH_2)_p-R_f$, while

p denotes one of the numbers 0, 1, 2 or 3 and

20 R_f denotes a hydroxycarbonyl, C₁₋₃-alkoxycarbonyl, aminocarbonyl,
C₁₋₃-alkylaminocarbonyl, C₁₋₃-alkyl)-aminocarbonyl or
C₃₋₇-cycloalkylamino-carbonyl group,

or

25

(ii) m denotes the number 0 or 1,
n denotes the number 0 and

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen
atoms independently of one another may be replaced in each case by a C₁₋₃-
30 alkyl group,

R₁ denotes an amino, C₁₋₃-alkylamino or C₃₋₇-cycloalkylamino group each of which
may be substituted at the amino nitrogen atom by a C₁₋₃-alkyl, C₁₋₃-alkylcarbonyl,

carboxy-C₁₋₃-alkyl, carboxy-C₁₋₃-alkylcarbonyl or C₁₋₆-alkoxy-carbonyl-C₁₋₃-alkyl-carbonyl group,

a di-(C₁₋₃-alkyl)amino or N-(C₅₋₇-cycloalkyl)-C₁₋₃-alkylamino group,

5

a 4- to 7-membered cycloalkyleneiminocarbonyl group optionally substituted by a C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, aminocarbonyl or C₁₋₃-alkylamino-carbonyl group, while

10 a hydrogen atom bound to a nitrogen atom may be replaced by an acetyl, phenylcarbonyl or tert.-butoxycarbonyl group,

a C₅₋₇-cycloalkyl-carbonyl group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, while

15

the hydrogen atom of the -NH group may be replaced by a C₁₋₃-alkyl, C₁₋₃-alkylcarbonyl or phenylcarbonyl group,

a phenylcarbonyl or heteroarylcarbonyl group,

20

wherein the heteroaryl moiety denotes a 6-membered heteroaryl group which contains one or two nitrogen atoms and to which a phenyl ring may be fused via one or two nitrogen atoms, while the bicyclic heteroaryl groups thus formed may be bound via the heteroaromatic or carbocyclic moiety, for example a 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinoliny, isoquinoliny, quinoxaliny or quinazoliny group,

25

a C₁₋₃-alkyl group optionally monosubstituted by a hydroxy or phenyl group or terminally disubstituted by a phenyl and a hydroxy group, wherein

30

the phenyl substituents may be substituted by an amidino group optionally substituted by one or two C₁₋₃-alkyl groups,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, trifluoromethyl or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

5

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group and

Ar denotes a phenyl group substituted by the groups R₅, R₆ and R₇, while

10 R₅ denotes a cyano group, an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, or an amino-C₁₋₃-alkyl or C₁₋₃-alkylamino-C₁₋₃-alkyl group,

15 R₆ denotes a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, C₁₋₃-alkyl, hydroxy, hydroxy-C₁₋₃-alkyl, C₁₋₃-alkoxy, carboxy, carboxy-C₁₋₃-alkoxy or C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkoxy group and

R₇ denotes a hydrogen atom or a C₁₋₃-alkyl group,

20 while the unsubstituted or monosubstituted phenyl groups mentioned in the definition of the abovementioned groups, or the unsubstituted or monosubstituted phenyl moieties contained in these groups, as well as the abovementioned heteroaryl groups may additionally be substituted at a carbon atom in each case by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, unless
25 otherwise stated,

the isomers and the salts thereof.

30 3. Compounds of general formula I according to claim 2, wherein

- (i) m denotes the number 0,
n denotes the number 1 and
A denotes a methylene group wherein

one or two hydrogen atoms independently of one another may be replaced
in each case by a C₁₋₃-alkyl group or

5 a hydrogen atom may be replaced by the group $-(CH_2)_p-R_f$, while

p denotes one of the numbers 0, 1, 2 or 3 and

R_f denotes a hydroxycarbonyl or C₁₋₃-alkoxycarbonyl group

10

or

(ii) m denotes the number 0,
n denotes the number 0 and

15 A denotes a -CH₂-CH₂- group, or

(iii) m denotes the number 1,
n denotes the number 0 and
A denotes a -CH₂- group,

20

the groups R₁ to R₄ are defined as in claim 2, but R₁ in the 4 position is bound to the
phenyl group contained in formula I and

Ar denotes a phenyl group disubstituted by the groups R₅ and R₆, while

25

R₅ is bound in the 3 position if R₆ denotes a hydrogen atom, or is bound in the 5
position if R₆ assumes a meaning other than the hydrogen atom, and denotes an
amidino group optionally substituted by one or two C₁₋₃-alkyl groups, a
C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, or an amino-C₁₋₃-alkyl or
30 C₁₋₃-alkylamino-C₁₋₃-alkyl group and

R₆ denotes a hydrogen atom or a hydroxy, C₁₋₃-alkoxy, carboxy-C₁₋₃-alkoxy or
C₁₋₄-alkoxy-carbonyl-C₁₋₃-alkoxy group bound in the 2 position,

the isomers and the salts thereof.

5 4. Compounds of general formula I according to claim 1, wherein

- (i) m denotes the number 0,
n denotes the number 1 and
A denotes a methylene group wherein

10

a hydrogen atom may be replaced by a methyl, hydroxycarbonyl or
C₁₋₃-alkoxy-carbonyl group,

R₁ is bound in the 4 position of the phenyl group of formula I and denotes

15

a C₅₋₇-cycloalkylamino group which may be substituted at the amino nitrogen atom by
a C₁₋₃-alkylcarbonyl, carboxy-C₁₋₃-alkylcarbonyl or C₁₋₄-alkoxy-carbonyl-
C₁₋₃-alkyl-carbonyl group,

20 a 4- to 7-membered cycloalkyleneiminocarbonyl group

R₂ denotes a hydrogen atom or a C₁₋₃-alkyl or trifluoromethyl group bound in the 3
position of the phenyl group in formula I,

25 R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group bound in the 2 position of the
phenyl group in formula I,

R₄ denotes a hydrogen atom and

30 Ar denotes a phenyl group disubstituted by the groups R₅ and R₆, while

R₅ is bound in the 3 position if R₆ denotes a hydrogen atom, or is bound in the 5
position if R₆ assumes a meaning other than the hydrogen atom, and denotes an

- 62 -

amidino group optionally substituted by a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group, and

R₆ denotes a hydrogen atom or a hydroxy group bound in the 2 position,

5

the isomers and the salts thereof.

5. Compounds of general formula I according to claim 1, wherein

10 (i) m denotes the number 0,
n denotes the number 0 and
A denotes a -CH₂-CH₂- group, or

(ii) m denotes the number 1,
15 n denotes the number 0 and
A denotes a -CH₂- group,

R₁ denotes a 4- to 7-membered cycloalkyleneiminocarbonyl group bound in the 4 position of the phenyl group of formula I,

20

R₂ denotes a hydrogen atom or a substituent selected from fluorine, chlorine, bromine, C₁₋₃-alkyl and trifluoromethyl bound in the 3 position of the phenyl group in formula I,

25 R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group bound in the 2 position of the phenyl group in formula I,

R₄ denotes a hydrogen atom and

30 Ar denotes a phenyl group disubstituted by the groups R₅ and R₆, wherein

R₅ is bound in the 5 position and denotes an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, a C₁₋₆-alkoxy-carbonyl or phenylcarbonyl group and

5 R₆ denotes a hydroxy group bound in the 2 position,

the isomers and the salts thereof.

6. The following compounds of general formula I according to claim 1:

10

(1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-ethylamine,

15

(2) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine,

(3) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzylamine,

20

(4) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,

(5) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,

25

(6) 2-(5-aminomethyl-2-hydroxy-benzyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)]-benzamide,

30

(7) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-ethoxycarbonylpropionyl)amino}]-benzamide,

(8) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-(N-acetyl-cyclobutylamino)]-benzamide,

- (9) 2-(5-carbamimidoyl-2-hydroxy-benzyl)-N-[3-methyl-4-{N-cyclopentyl-(3-carboxy-propionyl)amino}]-benzamide,
- (10) N-(5-carbamimidoyl-2-hydroxy-benzyl)-4-cyclopentylamino-3-methyl-benzamide,
- 5 (11) ethyl (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-amino)-acetate and
- (12) (3-carbamimidoyl-phenyl)-({1-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-carbonyl}-
- 10 amino)-acetic acid,
- while any amidino group present may additionally be substituted by a C₁₋₆-alkoxycarbonyl or phenylcarbonyl group, and the salts thereof.
- 15 7. Physiologically acceptable salts of the compounds according to claims 1 to 6 with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group.
8. Pharmaceutical compositions containing a compound according to at least one of
- 20 claims 1 to 6 with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group, or a salt according to claim 7 optionally together with one or more inert carriers and/or diluents.
- 25 9. Use of a compound according to at least one of claims 1 to 6 with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group, or a salt according to claim 7 for preparing a pharmaceutical composition with an antithrombotic activity.
- 30 10. Process for preparing a pharmaceutical composition according to claim 8, characterised in that a compound according to at least one of claims 1 to 6 with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, and R₅ denotes a cyano group, or a salt

- 65 -

according to claim 7 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

11. Process for preparing the compounds according to claims 1 to 7, characterised in
5 that

a) in order to prepare a compound of general formula I wherein

(i) m denotes the number 0, n denotes the number 1 and A denotes a straight-
10 chain C₁₋₃-alkylene group wherein

one or two hydrogen atoms independently of one another may be replaced
in each case by a C₁₋₃-alkyl group or

15 a hydrogen atom may be replaced by the group $-(CH_2)_p-R_f$, while p and R_f
are defined as in claims 1 to 6,

or

20 (ii) m and n each denote the number 1 and A denotes a bond and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while
R₆ and R₇ are defined as in claims 1 to 6 and R₅ denotes an amidino group,

25 a compound of general formula



wherein R₄ is defined as in claims 1 to 6,

30

A denotes a straight-chain C₁₋₃-alkylene group wherein one or two hydrogen atoms
independently of one another may be replaced in each case by a C₁₋₃-alkyl group or


- 66 -

a hydrogen atom may be replaced by the group $-(CH_2)_p-R_f$, while p and R_f are defined as in claims 1 to 6,

5 or A denotes a bond, and

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_5 denotes a cyano group and R_6 and R_7 are defined as in claims 1 to 6,

10 is acylated with a carboxylic acid of general formula



wherein m denotes the number 0 or 1 and R_1 to R_3 are defined as in claims 1 to 6, or
15 with the reactive derivatives thereof and the resulting cyano compound is then converted into an amidino compound or

b) in order to prepare a compound of general formula I wherein m denotes the number 0 or 1,

n denotes the number 0,


20 A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, and

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes an amidino group,

25

a compound of general formula

- 67 -



wherein R_1 to R_4 are defined as in claims 1 to 6 and m denotes the number 0 or 1,

is alkylated with a compound of general formula

5



wherein A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group,

10

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes a cyano group, and Z_1 denotes a leaving group and the resulting cyano compound is then converted into an amidino compound, or

15

c) in order to prepare a compound of general formula I wherein

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes an amidino group,

20

m denotes the number 1, n denotes the number 0 and


A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, or

25

m denotes the number 2, n denotes the number 0 and A denotes a bond,

a compound of general formula

- 68 -




wherein R_4 is defined as in claims 1 to 6,

A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms

5 independently of one another may be replaced in each case by a C_{1-3} -alkyl group, or denotes a bond, and

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes a cyano group,

10 is alkylated with a compound of general formula



wherein R_1 to R_3 are defined as in claims 1 to 6, m denotes the number 1 or 2 and

15 Z_2 denotes a leaving group, and the resulting cyano compound is then converted into an amidino compound or

d) in order to prepare a compound of general formula I wherein

20 Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes an amidino group,

m denotes the number 0 or 1, n denotes the number 0 and


A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms

25 independently of one another may be replaced in each case by a C_{1-3} -alkyl group, or

m denotes the number 2, n denotes the number 0 and A denotes a bond,


an amine of general formula

- 69 -



wherein R_1 to R_4 are defined as in claims 1 to 6 and m denotes the number 0, 1 or 2,
is reductively alkylated with an aldehyde of general formula

5



wherein A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen
atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl
group, or denotes a bond, and

10


Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while
 R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes a cyano group,
and the resulting cyano compound is then converted into an amidino compound, or

15

e) in order to prepare a compound of general formula I wherein Ar denotes a phenyl
or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are
defined as in claims 1 to 6 and R_5 denotes an amidino group optionally substituted by
one or two C_{1-3} -alkyl groups,

20

a compound of general formula



- 70 -

optionally formed in the reaction mixture

wherein

R_1 to R_4 , m , n and A are defined as in claims 1 to 6, Ar denotes a phenyl or naphthyl
5 group substituted by the groups R_6 and R_7 , while R_6 and R_7 are defined as in claims
1 to 6 and

Z_3 denotes an alkoxy, aralkoxy, alkylthio or aralkylthio group,

is reacted with an amine of general formula

10




wherein

R_8 and R_9 , which may be identical or different, each denote a hydrogen atom or a
15 C_{1-3} -alkyl group, or with a salt thereof or

f) in order to prepare a compound of general formula I wherein Ar denotes a phenyl
or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are
defined as in claims 1 to 6 and R_5 denotes an aminomethyl, C_{1-3} -alkylaminomethyl or
20 di- $(C_{1-3}$ -alkyl)aminomethyl group,


a compound of general formula



25 wherein

Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 ,
 R_1 to R_4 , R_6 , R_7 , A , m and n are defined as in claims 1 to 6 and
 R_5 denotes a cyano group,

is catalytically hydrogenated and optionally then alkylated with a compound of formula



5


wherein R_{10} denotes a C_{1-3} -alkyl group and Z_4 denotes a leaving group, or

g) in order to prepare a compound of general formula I wherein

- 10 m denotes the number 0, n denotes the number 0, A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, and Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 , while R_6 and R_7 are defined as in claims 1 to 6 and R_5 denotes an amidino group,

15


a compound of general formula



wherein

- 20 R_1 to R_3 are defined as in claims 1 to 6 and Z_5 denotes a leaving group,

is coupled with a compound of general formula



25

wherein R_4 is defined as in claims 1 to 6, A denotes a straight-chain C_{1-3} -alkylene group wherein one or two hydrogen atoms independently of one another may be replaced in each case by a C_{1-3} -alkyl group, and

Ar denotes a phenyl or naphthyl group substituted by the groups R₅, R₆ and R₇, while R₆ and R₇ are defined as in claims 1 to 6 and R₅ denotes a cyano group,

and then the cyano compound thus obtained is converted into an amidino compound,

5 and

subsequently, if desired, a compound of general formula I thus obtained which contains an amino or imino group is converted by means of a corresponding acyl derivative into a corresponding acyl compound of general formula I and/or

10

a compound of general formula I thus obtained which contains an esterified carboxy group is converted by hydrolysis into a corresponding carboxylic acid of general formula I and/or

15 a compound of general formula I thus obtained which contains a carboxy group is converted by esterification into a corresponding ester and/or

any protecting group used in order to protect reactive groups during the reactions is cleaved and/or

20


a compound of general formula I thus obtained is resolved into its stereoisomers and/or

a compound of general formula I thus obtained is converted into the salts thereof, particularly, for pharmaceutical use, into the physiologically acceptable salts thereof with an inorganic or organic acid or base.

25

Abstract

5 The present invention relates to antithrombotic compounds of general formula



10 wherein R_1 to R_4 , Ar, A, m and n are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof, the prodrugs and the salts thereof which have valuable properties.

The compounds of the above general formula I wherein Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 and R_5 denotes a cyano group are valuable intermediate products for preparing the corresponding compounds of general formula I wherein R_5 denotes an amidino group optionally substituted by one or two C_{1-3} -alkyl groups. The compounds of the above general formula I with the exception of those compounds wherein Ar denotes a phenyl or naphthyl group substituted by the groups R_5 , R_6 and R_7 and R_5 denotes a cyano group have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.